LY03020
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
LY03020 is a dual serotonin 5-HT 2C receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzheimer's disease. It is taken orally as a controlled-release formulation. The drug is under development by Luye Pharma Group. As of February 2026, it is in phase 1 clinical trials for both indications. The chemical structure of LY03020 does not yet appear to have been disclosed.
LY03020 is a dual serotonin 5-HT 2C receptor agonist and trace amine-associated receptor 1 (TAAR1) agonist which is under development for the treatment of schizophrenia and Alzheimer's disease. It is taken orally as a controlled-release formulation. The drug is under development by Luye Pharma Group. As of February 2026, it is in phase 1 clinical trials for both indications. The chemical structure of LY03020 does not yet appear to have been disclosed.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372022142 under CC BY-SA 4.0; modifications have been made.